In order to actively implement the "Technical Specifications for Tuberculosis Prevention and Control in China (2020 Edition)", first-line anti-tuberculosis drugs should be used for treatment of rifampicin-sensitive pulmonary tuberculosis patients without special circumstances, and anti-tuberculosis fixed-dose combination preparations (FDC) are recommended for treatment. requirements, improve the compliance of pulmonary tuberculosis patients, and reduce the incidence of drug-resistant tuberculosis. In response to the difficulty of using FDC in designated provincial and municipal tuberculosis hospitals, in April 2021, the China Antituberculosis Association launched the "Anti-tuberculosis Drug Fixed-dose Compound (FDC)" in five provinces including Jiangsu, Shandong, Jiangxi, Sichuan and Guizhou. Feasibility Pilot Project for Promotion and Use in Tuberculosis Specialized Hospitals”, to further understand the current status and feasibility of FDC use in provincial and municipal tuberculosis designated hospitals. In order to summarize the experience of the pilot project in a timely manner, introduce typical cases of the correct handling of the problems encountered in the clinical use of FDC, improve the understanding of the use of FDC, and accelerate the promotion and use of FDC in designated tuberculosis hospitals at all levels across the country, the China Antituberculosis Association in 2022. On July 28, a summary meeting and a seminar on promotion and application of FDC in designated TB hospitals were held offline and online. The meeting invited Zhao Yanlin, director of the Tuberculosis Prevention and Control Center of the Chinese Center for Disease Control and Prevention, deputy director Chen Mingting, Xu Caihong, director of the comprehensive business department, Zhou Lin, director of the patient care department, Liu Eryong, deputy director, Wang Ni, deputy director of the application technology department, and vice chairman of the China Antituberculosis Association. and Secretary-General Cheng Shiming, Deputy Secretary-General Fan Haiying, Ding Weimin, Director of the Endoscopy Center, Beijing Chest Hospital Affiliated to Capital Medical University, Lu Yu, Director of the Pharmacology Research Office, and Zhu Limei, Deputy Director of the Institute of Chronic Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention , Zeng Yi, Director of the Tuberculosis Department of Nanjing Second Hospital, Wu Guihui, Director of the Tuberculosis Department of Chengdu Public Health Clinical Medical Center, Ye Jiaqing, Tuberculosis Prevention and Control Institute of Jiangxi Provincial Center for Disease Control and Prevention, Geng Hong, Director of Prevention and Control Department of Shandong Provincial Public Health Clinical Center, Guizhou Guo Xiaohong, Vice President of the Third People's Hospital of Liupanshui City, Yang Rui, Chief Physician of the Tuberculosis Prevention and Control Institute of Yunnan Provincial Center for Disease Control and Prevention, and Shenyang Hongqi Pharmaceutical Co., Ltd. Representatives of the company and Zhejiang Su Ke'an Pharmaceutical Co., Ltd., a member of the enterprise director unit of the China Antituberculosis Association, attended the meeting. At the same time, 11,604 experts and scholars participated in the meeting online through the Internet platform of the Home of Science and Technology Workers.

Panorama of Beijing venue

Panorama of online meeting

    Director Zhao Yanlin pointed out in his speech that FDC has shown in a large number of applied studies that FDC can improve the compliance of patients with treatment. The simultaneous use of FDC can ensure the combination of drugs, thereby controlling the occurrence of drug-resistant tuberculosis.

Zhao Yanlin, Director of the Tuberculosis Prevention and Control Center of the Chinese Center for Disease Control and Prevention, delivered a speech

   "Report on the Feasibility Pilot Project of the Promotion and Use of Fixed-dose Compounds of Anti-tuberculosis Drugs in Designated Tuberculosis Hospitals"

    The keynote report on the pilot study of the conference was chaired by Chen Mingting, Deputy Director of the Nuclear Disease Prevention and Control Center of the Chinese Center for Disease Control and Prevention, and Wang Nizuo, Deputy Director of the Applied Technology Department of the Center for Disease Control and Prevention of the Chinese Center for Disease Control and Prevention Feasibility Pilot Project Report for Use. The report pointed out that it is necessary to further promote the use of anti-tuberculosis FDC in the country and maintain a high utilization rate, improve the drug supply management system of medical and preventive cooperation, and recommend increasing publicity to improve patients' awareness of standardized treatment, and gradually promote the use of video supervision, New tools such as electronic pill box supervision assist patients with medication management and improve patient acceptance and treatment compliance.

Tuberculosis Prevention and Control Center, Chinese Center for Disease Control and Prevention

Deputy Director Chen Mingting presided over the keynote report on the pilot study

Department of Applied Technology, TB Control Center, Chinese Center for Disease Control and Prevention

Deputy Director Wang Ni

   "Expert Consensus Interpretation and Use Case Analysis of Clinical Use of Anti-TB FDC"

    Zhou Lin, Director of the Patient Care Department of the Tuberculosis Prevention and Control Center of the Chinese Center for Disease Control and Prevention, made a report on "Expert Consensus Interpretation and Use Case Analysis for Clinical Use of Anti-TB FDC". The introduction of fixed-dose compound preparations, the significance of using FDC, the application of FDC in my country, the possible drugs and treatment of FDC adverse reactions, and clinical case analysis were introduced, and corresponding treatment opinions and suggestions were put forward in turn.

Tuberculosis Prevention and Control Center, Chinese Center for Disease Control and Prevention

Zhou Lin, Director of Patient Care Department

   "Re-understanding FDC: FDC's Evidence-Based and Clinical Drug Experience Sharing"

    Ding Weimin, director of the Endoscopy Center of Beijing Chest Hospital Affiliated to Capital Medical University, and Zhu Limei, deputy director of the Institute of Chronic Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, co-chaired the pilot research experience sharing. Experts from FDC pilot units in 5 different provinces The pilot research experience was shared in turn, and questions and discussions were conducted with online experts and scholars.

Ding Weimin, director of the Endoscopy Center, Beijing Chest Hospital Affiliated to Capital Medical University, and Zhu Limei, deputy director of the Institute of Chronic Infectious Disease Control, Jiangsu Center for Disease Control and Prevention, co-chaired the meeting.

Zeng Yi, Director of the Tuberculosis Department of Nanjing Second Hospital

"Chengdu Public Health FDC Clinical Application Experience Sharing"

Wu Guihui, Director of the Tuberculosis Department of Chengdu Public Health Clinical Medical Center

    Cheng Shiming, vice chairman and secretary general of the China Antituberculosis Association, made a summary of the meeting. She said that the online and offline experts of this meeting discussed the practical application of FDC through various forms such as theoretical teaching, experience sharing and case discussion. And put forward very good suggestions. I hope to investigate the current situation and existing problems of FDC use in the future, strengthen the training of medical staff, expand the popularization and education of patients, put funds in place, strengthen policy development and formulation, and do a good job in FDC. Use evaluation and promotion. Experts inspire each other and work together, and the association will work with scientists and anti-tuberculosis companies to achieve the goal of ending tuberculosis as soon as possible.